Minerva Neurosciences, Inc. (NASDAQ: NERV) announced positive top line results from a Phase Ib clinical trial in major depressive disorder ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Minerva Neurosciences (NERV) Misses Q4 EPS by 3cMarch 14, 2016 7:32 AM Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202March 11, 2016 8:30 AM